MSB Q2 Financial Results and Operational Highlights
Filed with ASX · · 8 pages · English
In the deck
Story so far
Earlier from Mesoblast
- Half Year Financial Results Presentation
- FDA Grants Orphan Drug Designation for Revascor
- FDA Grants Rare Pediatric Disease Designation for Revascor
- Information For Retail Shareholders
- Mesoblast Completes Institutional Allocation
Later from Mesoblast
- FDA Supports Accelerated Approval Pathway for Heart Failure
- Mesoblast Completes Placement and Entitlement Offer
- FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
- Mesoblast Resubmits BLA with FDA for Ryoncil Approval
- FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast